Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.64 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29832812 | 1.00 | CHRNB2 (0.64) | CHRNB2CHRNA4LMNAHPGDMEN1 | |
| SCHEMBL5518334 | 0.95 | CHRNB2 (0.62) | CHRNB2CHRNA4LMNAHPGDMEN1 | |
| SCHEMBL31087898 | 0.95 | CHRNB2 (0.62) | CHRNB2CHRNA4LMNAHPGDMEN1 | |
| SCHEMBL31087900 | 0.94 | CHRNB2 (0.61) | CHRNB2CHRNA4LMNAHPGDMEN1 | |
| SCHEMBL31087905 | 0.94 | CHRNB2 (0.61) | CHRNB2CHRNA4LMNAHPGDMEN1 | |
| SCHEMBL8955653 | 0.94 | CHRNB2 (0.61) | CHRNB2CHRNA4LMNAHPGDMEN1 | |
| SCHEMBL77341 | 0.92 | CHRNB2 (0.66) | CHRNB2CHRNA4LMNAHPGDMEN1 | |
| SCHEMBL14028449 | 0.88 | CHRNB2 (0.69) | CHRNB2CHRNA4LMNAHPGDMEN1 | |
| SCHEMBL15498199 | 0.88 | CHRNB2 (0.73) | CHRNB2CHRNA4LMNAHPGDMEN1 | |
| SCHEMBL9561277 | 0.86 | CHRNB2 (0.59) | CHRNB2CHRNA4LMNAHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108117503-B | Novel pyrrole sulfonyl chemical entity, preparation method and application thereof | 江苏柯菲平医药股份有限公司 | 2022-09-02 | — | — | CN | disclosed |
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | disclosed |
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | disclosed |
| US-20130116318-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| US-20130116318-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| EP-1879895-B1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2011-06-08 | — | — | EP | disclosed |
| US-7939666-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-05-10 | — | — | US | disclosed |
| US-7939666-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-05-10 | — | — | US | disclosed |
| EP-2301939-A1 | Enzyme inhibitors | Chroma Therapeutics Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20090291978-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | US | disclosed |
| US-20090291978-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | US | disclosed |
| US-20070185135-A1 | Drug-Polymer Conjugates | PHARMAESSENTIA CORP. | 2007-08-09 | — | — | US | disclosed |
| WO-2006117549-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116318-A1 | Enzyme Inhibitors | HDAC1, HDAC11, HDAC7 | CHRNB2 4359/4885CHRNA4 4551/4885LMNA 2584/4885 |
| US-20070185135-A1 | Drug-Polymer Conjugates | LNPEP, MSN, ANPEP | CHRNB2 2507/4885CHRNA4 3558/4885LMNA 2588/4885 |
| US-20140163042-A1 | ENZYME INHIBITORS | HAT1, NR2E1, HDAC3 | CHRNB2 335/4885CHRNA4 225/4885LMNA 885/4885 |
| US-20090291978-A1 | Enzyme Inhibitors | HAT1, NR2E1, NR2C2 | CHRNB2 440/4885CHRNA4 477/4885LMNA 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.